tiprankstipranks
Cizzle Biotech Partners with BBI for Cancer Detection
Company Announcements

Cizzle Biotech Partners with BBI for Cancer Detection

Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.

Pick the best stocks and maximize your portfolio:

Cizzle Biotechnology Holdings PLC has formed a strategic partnership with BBI Solutions to manufacture monoclonal antibodies for a lung cancer detection test. The collaboration aims to supply the first commercial batch of antibodies, supporting up to 5000 assays, and is a critical step toward the commercialization and regulatory strategy of the company. This advancement is set to aid in early detection of lung cancer, with potential expansion into other cancer detection tests.

For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskCizzle Biotechnology Expands Lung Cancer Diagnostic Reach to the Caribbean
TipRanks UK Auto-Generated NewsdeskCizzle Biotechnology Enters Strategic North American Partnership
TipRanks UK Auto-Generated NewsdeskCizzle Biotech Nears Major US Licensing Deal
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App